DelveInsight’s, “Transforming Growth Factor Beta Inhibitors Pipeline Insight” report provides comprehensive insights about 90+ companies and 90+ pipeline drugs in Transforming Growth Factor Beta Inhibitors pipeline landscape. It covers the Transforming Growth Factor Beta Inhibitors pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Transforming Growth Factor Beta Inhibitors therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive Transforming Growth Factor Beta Inhibitors pipeline products in this space.
Stay ahead with the latest insights! Download DelveInsight’s comprehensive Transforming Growth Factor Beta Inhibitors Pipeline Report to explore emerging therapies, key Transforming Growth Factor Beta Inhibitors Companies, and future Transforming Growth Factor Beta Inhibitors treatment landscapes @ Transforming Growth Factor Beta Inhibitors Pipeline Outlook Report
Key Takeaways from the Transforming Growth Factor Beta Inhibitors Pipeline Report
- DelveInsight’s Transforming Growth Factor Beta Inhibitors pipeline report depicts a robust space with 90+ active players working to develop 90+ pipeline therapies for Transforming Growth Factor Beta Inhibitors treatment.
- The leading Transforming Growth Factor Beta Inhibitors Companies such as Oncotelic, Jiangsu Hengrui Medicine Co., Bristol-Myers Squibb/Rigel, Biogen Idec, Genentech, Tilos Therapeutics, Eli Lilly and Company, and others.
- Promising Transforming Growth Factor Beta Inhibitors Therapies such as Trabedersen, KER-050, STP705, and others.
Discover how the Transforming Growth Factor Beta Inhibitors treatment paradigm is evolving. Access DelveInsight’s in-depth Transforming Growth Factor Beta Inhibitors Pipeline Analysis for a closer look at promising breakthroughs @ Transforming Growth Factor Beta Inhibitors Clinical Trials and Studies
Transforming Growth Factor Beta Inhibitors Emerging Drugs Profile
- Trabedersen: Oncotelic
Trabedersen (OT-101) is a single-stranded phosphorothioate antisense oligodeoxynucleotide (18-mer) targeting the human TGF-β2 messenger RNA. Ready for registration trials–Over 200 patients treated across 6 clinical trials. It has Potential for breakthrough designation for early approval. It is in phase III stage of development.
- KER-050: Keros Therapeutics
KER-050, is an engineered ligand trap comprised of a modified ligand-binding domain of the TGF-β receptor known as activin receptor type IIA that is fused to the portion of the human antibody known as the Fc domain. KER-050 is designed to increase red blood cell and platelet production by inhibiting the signaling of a subset of the TGF-β family of proteins to promote hematopoiesis. It is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes and myelofibrosis.
- STP705: Sirnaomics
STP705 is delivered intradermally to the tumor site resulting in localized silencing of TGF-b1 and Cox-2, killing of the tumor cells and a reduction in tumor size. It is currently in phase II stage of development.
Get a detailed analysis of the latest innovations in the Transforming Growth Factor Beta Inhibitors pipeline. Explore DelveInsight’s expert-driven report today! @ Transforming Growth Factor Beta Inhibitors Unmet Needs
Transforming Growth Factor Beta Inhibitors Companies
Oncotelic, Jiangsu Hengrui Medicine Co., Bristol-Myers Squibb/Rigel, Biogen Idec, Genentech, Tilos Therapeutics, Eli Lilly and Company, and others.
Transforming Growth Factor Beta Inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Infusion
- Intradermal
- Intramuscular
- Intranasal
- Oral
- Parenteral
- Subcutaneous
- Topical.
- Molecule Type
Transforming Growth Factor Beta Inhibitors Products have been categorized under various Molecule types such as
- Gene therapies
- Small molecule
- Vaccines
- Polymers
- Peptides
- Monoclonal antibodies
- Product Type
Download DelveInsight’s latest report to gain strategic insights into upcoming Transforming Growth Factor Beta Inhibitors Therapies and key Transforming Growth Factor Beta Inhibitors Developments @ Transforming Growth Factor Beta Inhibitors Market Drivers and Barriers, and Future Perspectives
Scope of the Transforming Growth Factor Beta Inhibitors Pipeline Report
- Coverage- Global
- Transforming Growth Factor Beta Inhibitors Companies- Oncotelic, Jiangsu Hengrui Medicine Co., Bristol-Myers Squibb/Rigel, Biogen Idec, Genentech, Tilos Therapeutics, Eli Lilly and Company, and others.
- Transforming Growth Factor Beta Inhibitors Therapies- Trabedersen, KER-050, STP705, and others.
- Transforming Growth Factor Beta Inhibitors Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
- Transforming Growth Factor Beta Inhibitors Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Which companies are leading the race in Transforming Growth Factor Beta Inhibitors drug development? Find out in DelveInsight’s exclusive Transforming Growth Factor Beta Inhibitors Pipeline Report—access it now! @ Transforming Growth Factor Beta Inhibitors Emerging Drugs and Major Companies
Table of Content
- Introduction
- Executive Summary
- Transforming growth factor beta inhibitors: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Transforming growth factor beta inhibitors – DelveInsight’s Analytical Perspective
- In-depth Commercial Assessment
- Transforming growth factor beta inhibitors Collaboration Deals
- Late Stage Products (Phase III)
- Trabedersen: Oncotelic
- Mid Stage Products (Phase II)
- KER-050: Keros Therapeutics
- STP705: Sirnaomics
- Early Stage Products (Phase I)
- Drug Name: Company Name
- Drug profiles in the detailed report…..
- Pre-clinical and Discovery Stage Products
- Drug Name: Company Name
- Inactive Products
- Transforming growth factor beta inhibitors Key Companies
- Transforming growth factor beta inhibitors Key Products
- Transforming growth factor beta inhibitors- Unmet Needs
- Transforming growth factor beta inhibitors- Market Drivers and Barriers
- Transforming growth factor beta inhibitors- Future Perspectives and Conclusion
- Transforming growth factor beta inhibitors Analyst Views
- Transforming growth factor beta inhibitors Key Companies
- Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/venous-thromboembolism-market